By a nose: Menlo Park company moves from nasal devices to drugs with latest approval

Intersect ENT Inc. won Food and Drug Administration approval for a sinus implant that delivers an anti-inflammatory steroid to treat nasal polyps. It isn't the Menlo Park company's (NASDAQ: XENT) first product to be greenlighted by regulators — Intersect's previous three products were medical devices — but it is the first to be approved as a drug. Sinuva is placed within a sinus implant, which is put in during a routine visit to a docto r's office. It expands into the sinus cavity and delivers…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news